CervoMed To Present Neflamapimod, Oral, Small Molecule, Drug Candidate Targeting Critical Disease Processes Underlying Degenerative Disorders Of Brain, At ISFTD Annual Meeting
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual MeetingnfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology,
CervoMed is showing early test results for a new brain medicine at a big doctor meeting. When a company presents research like this, it is good to watch if doctors think the results look promising.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.